TrialThe Journal of clinical investigation2020
Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.
Corey Smith et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
48 papers cite it
this paperpooled itcites it